CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,226,945 | +13.6% | 93,125 | +13.2% | 0.00% | 0.0% |
Q2 2023 | $3,721,796 | 0.0% | 82,286 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $3,721,796 | +20.6% | 82,286 | +8.4% | 0.00% | 0.0% |
Q4 2022 | $3,085,579 | -99.9% | 75,906 | +0.2% | 0.00% | -33.3% |
Q3 2022 | $4,952,615,000 | -38.8% | 75,786 | -43.1% | 0.00% | -25.0% |
Q2 2022 | $8,091,770,000 | +8.0% | 133,154 | +11.6% | 0.00% | +33.3% |
Q1 2022 | $7,490,156,000 | -17.3% | 119,327 | -0.2% | 0.00% | 0.0% |
Q4 2021 | $9,058,212,000 | -29.3% | 119,533 | +4.5% | 0.00% | -40.0% |
Q3 2021 | $12,807,032,000 | -32.5% | 114,420 | -2.4% | 0.01% | -37.5% |
Q2 2021 | $18,975,612,000 | +10.4% | 117,213 | -16.9% | 0.01% | 0.0% |
Q1 2021 | $17,187,429,000 | +5.2% | 141,054 | +32.1% | 0.01% | 0.0% |
Q4 2020 | $16,343,881,000 | +62.0% | 106,746 | -11.5% | 0.01% | +60.0% |
Q3 2020 | $10,086,316,000 | -1.3% | 120,592 | -13.3% | 0.01% | -16.7% |
Q2 2020 | $10,217,314,000 | +84.9% | 139,030 | +6.7% | 0.01% | +50.0% |
Q1 2020 | $5,527,211,000 | – | 130,328 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |